A systematic review of the utility of amino acid PET in assessing treatment response to bevacizumab in recurrent high-grade glioma

Background. Currently, bevacizumab (BEV), an antiangiogenic agent, is used as an adjunctive therapy to re-irradiation and surgery in patients with recurrent high-grade gliomas (rHGG). BEV has shown to decrease enhancement on MRI, but it is often unclear if these changes are due to tumor response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hughes, Kendall L, O’Neal, Christen M, Andrews, Bethany J, Westrup, Alison M, Battiste, James D, Glenn, Chad A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369430/
https://www.ncbi.nlm.nih.gov/pubmed/34409294
http://dx.doi.org/10.1093/noajnl/vdab003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369430/
https://www.ncbi.nlm.nih.gov/pubmed/34409294
http://dx.doi.org/10.1093/noajnl/vdab003

Ejemplares similares